Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 568980, 7 pages
http://dx.doi.org/10.1155/2015/568980
Research Article

Prognostic Value of High CXCR4 Expression in Renal Cell Carcinoma: A System Review and Meta-Analysis

Department of Urology, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, China

Received 21 June 2015; Revised 1 September 2015; Accepted 2 September 2015

Academic Editor: Stamatios Theocharis

Copyright © 2015 Yuefeng Du et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. E. Desantis, C. C. Lin, A. B. Mariotto et al., “Cancer treatment and survivorship statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 4, pp. 252–271, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. H. An, L. Xu, Y. Zhu et al., “High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma,” British Journal of Cancer, vol. 110, no. 9, pp. 2261–2268, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. G. D. Stewart, F. C. O'Mahony, T. Powles, A. C. P. Riddick, D. J. Harrison, and D. Faratian, “What can molecular pathology contribute to the management of renal cell carcinoma?” Nature Reviews Urology, vol. 8, no. 5, pp. 255–265, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. I. Karakiewicz, A. Briganti, F. K.-H. Chun et al., “Multi-institutional validation of a new renal cancer-specific survival nomogram,” Journal of Clinical Oncology, vol. 25, no. 11, pp. 1316–1322, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Garcia and B. I. Rini, “Recent progress in the management of advanced renal cell carcinoma,” CA Cancer Journal for Clinicians, vol. 57, no. 2, pp. 112–125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. L. J. Costa and H. A. Drabkin, “Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies,” Oncologist, vol. 12, no. 12, pp. 1404–1415, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. W. M. Linehan, “Targeting VEGF receptors in kidney cancer,” The Lancet Oncology, vol. 8, no. 11, pp. 956–957, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone, “Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions,” Oncologist, vol. 11, no. 7, pp. 753–764, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Brugarolas, “Renal-cell carcinoma—molecular pathways and therapies,” The New England Journal of Medicine, vol. 356, no. 2, pp. 185–187, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. C. L. Richard and J. Blay, “CXCR4 in cancer and its regulation by PPARγ,” PPAR Research, vol. 2008, Article ID 769413, 19 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Li, Y. Huang, J. Xia et al., “Cxcr4 expression in patients with high-risk locally advanced renal cell carcinoma can independently predict increased risk of disease progression and poor overall survival,” Asian Pacific Journal of Cancer Prevention, vol. 12, no. 12, pp. 3313–3318, 2011. View at Google Scholar · View at Scopus
  12. T. Nagasawa, “CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4,” Journal of Molecular Medicine, vol. 92, no. 5, pp. 433–439, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Kim, T. Mori, S. L. Chen et al., “Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome,” Annals of Surgery, vol. 244, no. 1, pp. 113–120, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Maréchal, P. Demetter, N. Nagy et al., “High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma,” British Journal of Cancer, vol. 100, no. 9, pp. 1444–1451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Wang, L. Wang, B. Yang et al., “Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis,” Clinical and Experimental Metastasis, vol. 26, no. 8, pp. 1049–1054, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. F.-L. Zhao and W. Guo, “Expression of stromal derived factor-1 (SDF-1) and chemokine receptor (CXCR4) in bone metastasis of renal carcinoma,” Molecular Biology Reports, vol. 38, no. 2, pp. 1039–1045, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. C. D'Alterio, L. Cindolo, L. Portella et al., “Differential role of CD133 and CXCR4 in renal cell carcinoma,” Cell Cycle, vol. 9, no. 22, pp. 4492–4500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. D'Alterio, C. Consales, M. Polimeno et al., “Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer,” Current Cancer Drug Targets, vol. 10, no. 7, pp. 772–781, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. D'Alterio, L. Portella, A. Ottaiano et al., “High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer,” Current Cancer Drug Targets, vol. 12, no. 6, pp. 693–702, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Li, G. Badin, A. Zhao et al., “Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma,” Histology and Histopathology, vol. 28, no. 9, pp. 1217–1222, 2013. View at Google Scholar · View at Scopus
  21. L. Wang, W. Chen, L. Gao et al., “High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma,” World Journal of Surgical Oncology, vol. 10, article 212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Tachibana, S. Hirota, H. Iizasa et al., “The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract,” Nature, vol. 393, no. 6685, pp. 591–594, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Furusato, A. Mohamed, M. Uhlén, and J. S. Rhim, “CXCR4 and cancer,” Pathology International, vol. 60, no. 7, pp. 497–505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. T. C. Wehler, C. Graf, S. Biesterfeld et al., “Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease,” Journal of Oncology, vol. 2008, Article ID 626340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Staller, J. Sulitkova, J. Lisztwan, H. Moch, E. J. Oakeley, and W. Krek, “Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL,” Nature, vol. 425, no. 6955, pp. 307–311, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. J. C. Gahan, M. Gosalbez, T. Yates et al., “Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis,” The Journal of Urology, vol. 187, no. 3, pp. 827–833, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Pan, J. Mestas, M. D. Burdick et al., “Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis,” Molecular Cancer, vol. 5, article 56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Guo, B. Tang, X. N. Sheng, and C. L. Cui, “Use of CXCR4 expression to predict the efficacy of sorafenib treatment in patients with metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 359–364, 2011. View at Google Scholar
  29. M. Han, S. Lv, Y. Zhang et al., “The prognosis and clinicopathology of CXCR4 in gastric cancer patients: a meta-analysis,” Tumor Biology, vol. 35, no. 5, pp. 4589–4597, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. C.-F. Liu, S.-Y. Liu, X.-Y. Min et al., “The prognostic value of CXCR4 in ovarian cancer: a meta-analysis,” PLoS ONE, vol. 9, no. 3, Article ID e92629, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Wu, X. Fu, X. Zhu et al., “Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 5, pp. 887–896, 2011. View at Publisher · View at Google Scholar · View at Scopus